GeNeuro SA: Extension of the debt restructuring stay until 2026

Geneva-based biopharmaceutical company GeNeuro SA has obtained an extension of its definitive stay of insolvency proceedings. The Geneva Court of First Instance granted the company an extension until January 27, 2026. This decision allows the company to continue its financial restructuring efforts under the supervision of a court-appointed administrator.

Initially granted in May 2025, the suspension was intended to assess options such as recapitalization and asset monetization. GeNeuro SA is focused on maximizing value for its stakeholders while developing innovative treatments for neurodegenerative and autoimmune diseases. The postponement of the publication of the 2024 annual results is also planned to integrate the impacts of this restructuring.